🔴 Xenetic Biosciences is trading 7.36% down today in pre-market amid proposed Santersus acquisition volatility

Xenetic Biosciences is trading 7.36% down now at $2.77 in pre-market amid volatility around its proposed all-stock acquisition of Santersus AG.

• Existing shareholders would receive approximately 15% of the combined company, while Santersus holders would receive approximately 85%, subject to adjustments.
• The transaction remains subject to stockholder and regulatory approvals and is expected to close in the fourth quarter of 2026.
• The decline follows a rebound from $2.19 on September 16 to $2.99 on September 21; no separate September 22 company announcement was identified.